Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Capecitabine/Gemcitabine and Chemoradiation in EHCC
NCT00789958Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Dec 2008
- Primary completion
- Dec 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, gemcitabine in extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer, sponsored by SWOG Cancer Research Network. Started Dec 2008; status: completed.
02
Drugs
capecitabinegemcitabine
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on NCT00789958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789958.